• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Inspira(TM) Technologies Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

    12/22/22 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care
    Get the next $IINN alert in real time by email

    ORLANDO, FL / ACCESSWIRE / December 22, 2022 / RedChip Companies will air a new interview with Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Interview highlights:

    In the exclusive RedChip Money Report interview, Inspira™ Technologies' Co-Founder & President Joe Hayon discusses how Inspira's technology could reduce the need for invasive mechanical ventilation, plans to begin human studies at leading medical centers, how the technology could become the new potential standard of care for acute respiratory failure, and much more.

    Access this interview in its entirety at https://www.iinninfo.com/interview_access

    About The RedChip Money Report®

    The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

    About Inspira™ Technologies

    Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company is researching and developing a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while minimizing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and have not been approved by any regulatory entity.

    For more information, please visit our corporate website:

    https://inspira-technologies.com/

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Forward Looking Statements

    This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when its regulatory strategy, the expected timing of its clinical study, the expected benefits to patients of its products, the belief that the potential use of the HYLA blood sensor for multiple hospital settings increases its potential commercial appeal as a standalone device, that it expects to add the HYLA blood sensor to its INSPIRA ART system and that the HYLA blood sensor has significant potential to make a meaningful impact on real-time patient monitoring. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, www.sec.gov

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/733006/InspiraTM-Technologies-Interview-to-Air-on-Bloomberg-US-on-the-RedChip-Money-ReportR

    Get the next $IINN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IINN

    DatePrice TargetRatingAnalyst
    11/1/2021$9.00 → $10.00Buy
    Aegis Capital
    8/26/2021$9.00Buy
    Aegis Capital
    More analyst ratings

    $IINN
    SEC Filings

    View All

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    12/9/25 8:32:33 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    12/3/25 8:39:30 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form F-3/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    F-3/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    11/25/25 5:03:49 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use

    RA'ANANA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that the Japan Patent Office has granted Patent No. 7777598. This patent covers the Company's novel Convertible Dual Lumen Cannula device and method of use, securing exclusive rights in one of the world's most advanced medical device markets. The patent grants Inspira exclusive commercial rights in the patented Dual Lumen Cannula technology in Japan through 2041. This milestone complements the Company's existing U.S. Patent (granted in 2023), further e

    12/9/25 8:05:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Technologies Announces Strategic Leap in Lab Capabilities – Accelerating Next-Generation Diagnostics and Blood Technology

    RA'ANANA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic expansion of its core blood laboratory capabilities, marking a substantial step in the Company's evolution into a broader cutting edge technologies, positioning it for accelerated future growth. The strategic expansion includes transitioning to a substantially larger, state-of-the-art laboratory facility, while planning to increase recruitment of specialized personnel, upgrading advanced research instrumentation, and expanding its operation

    12/3/25 8:43:08 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission

    RA'ANANA, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the completion of the clinical study for its HYLA,  non-invasive blood sensor, toward regulatory submission and future commercialization. Based on the clinical trial results and ongoing lab tests, showing between 95% to 99% accuracy across measured parameters, Inspira is soon entering the final validation and verification stage ahead of planned regulatory submission. Inspira is leveraging its proprietary non-invasive platform and integrating advanced

    11/13/25 9:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on Inspira Technologies Oxy with a new price target

    Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously

    11/1/21 12:39:26 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Aegis Capital initiated coverage on Inspira Technologies Oxy with a new price target

    Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00

    8/26/21 10:05:11 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Financials

    Live finance-specific insights

    View All

    Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

    RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update. "The first half of 2025 represents a pivotal transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution. Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 millio

    10/1/25 8:00:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates

    Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system an

    3/11/25 8:30:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira™ Announces Business Plan Targets

    Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel, June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. Joe Hayon, presented a business plan with targets for the Company's next-generation technologies on a Company conference call today.     On the call, Inspira unveiled plans to build an opportunity for a share of the $19 billion mechanical ventilation market. Inspira's

    6/20/24 9:25:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Leadership Updates

    Live Leadership Updates

    View All

    Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm

    RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als

    10/21/25 3:40:00 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm

    RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als

    10/21/25 9:05:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    PESG Report: Inspira Technologies Strengthens its AI-Powered Blood Sensor with new Capabilities, Intends to Share Clinical Findings Soon

    Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth $34 billion - a 35% increase year-over-year. The integration of this new oxygenation indicator strengthens the Company's position in both the $2.5 billion blood gas analysis market and, through the FDA-cleared INSPIRA ART100 system, the $19 billion mechanical ventilation market. With clinical evaluations of the HYLA blood sensor underway at Sheba Medical Center and preliminary results reportedly expected in the near future, the Company continues to execute its strategy of combining AI-enhanced monitoring capabilities with inn

    2/6/25 8:27:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $IINN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    11/14/24 4:08:42 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/14/24 3:40:01 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd. (Amendment)

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    2/12/24 4:05:09 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care